Trial Treatments

The treatments were chosen after carefully looking at all the available evidence that has been published about them. We looked at evidence about their safety, as well as evidence from other clinical studies. People with Parkinson’s and care partners were involved in the discussions and advised on what would be acceptable to participants. We believe these treatments could be the most promising treatments to slow or stop PD symptoms from getting worse.

The trial treatments currently being tested in the EJS ACT-PD trial are:

Group A: Placebo (or dummy drug)
Group B: Telmisartan (40mg per day)
Group C: Terazosin (5mg per day)

This trial design also allows us to add new treatments in new treatment groups whilst the trial is ongoing, rather than needing to set up a new trial.

If you are interested in participating in the EJS ACT-PD trial, follow the link to complete the Registration of Interest. (Please note the link will be made available at a later date)

Trial Treatments

The trial treatments currently being tested in the EJS ACT-PD trial are:

Group A: Placebo (or dummy drug)

Group B: Telmisartan (40mg per day)

Group C: Terazosin (5mg per day)

This trial design also allows us to add new treatments in new treatment groups whilst the trial is ongoing, rather than needing to set up a new trial.